Prestige BioPharma Limited (KRX:950210)

Market Cap	148.44B
Revenue (ttm)	14.41B
Net Income (ttm)	15.76B
Shares Out	12.02M
EPS (ttm)	262.37
PE Ratio	47.07
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111,214
Average Volume	132,469
Open	12,540
Previous Close	12,550
Day's Range	12,210 - 12,660
52-Week Range	11,000 - 20,000
Beta	0.98
RSI	42.46
Earnings Date	Feb 27, 2026

About Prestige BioPharma

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Country: Singapore
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 950210